Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biolojic Design

- PMLiVE

Lilly ends $1.4bn deal with immuno-oncology biotech NextCure

Lilly paid $25m upfront on top of a $15m equity investment

- PMLiVE

Lilly extends range of cut-price insulins in the US

Announces discounts in response to increasing pricing criticism

- PMLiVE

Lilly expands dermatology portfolio with $1.1bn Dermira deal

Deal includes FDA fast-tracked eczema drug

Sanofi reception

Sanofi narrows focus, shedding diabetes and cardiovascular research

New CEO Paul Hudson reveals strategy update

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

- PMLiVE

New hires at Amgen, Eli Lilly and Zosano

The latest movers in pharma

Eli Lilly HQ

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Company still hopes drug can show promise in other cancer types

- PMLiVE

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Company says decision is not related to Brexit

- PMLiVE

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

FDA clears Lilly’s Taltz for ankylosing spondylitis

New indication boosts $1bn+ hopes for this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links